有机化学 ›› 2011, Vol. 31 ›› Issue (03): 312-316. 上一篇    下一篇

研究论文

基于Chlamydocin骨架设计合成环肽类HDACi及其抗肿瘤活性

李晓晖*,1,2黄大卫1孙蕾1修志龙1西野宪和2   

  1. (1大连理工大学生命科学与技术学院 大连 116024)
    (2日本九州工业大学大学院生命体工学研究科 北九州 808-0196)
  • 收稿日期:2010-05-04 修回日期:2010-09-28 发布日期:2010-10-09
  • 通讯作者: 修志龙 E-mail:zhlxiu@dlut.edu.cn
  • 基金资助:

    国家“863”计划项目

Design, Synthesis and Antitumor Activity of Cyclic Tetrapeptide HDACi Based on Chlamydocin

Li Xiaohui*,1,2 Huang Dawei1 Sun Lei1 Xiu Zhilong1 Norikazu Nishino2   

  1. (1 School of Life Science and Biotechnology, Dalian University of Technology, Dalian 116024)
    (2 Graduate School of Life Science and Systems Engineering, Kyushu Institute of Technology, Kitakyushu 808-0196)
  • Received:2010-05-04 Revised:2010-09-28 Published:2010-10-09

组蛋白去乙酰化酶(HDACs)通过催化各种底物蛋白包括组蛋白、转录因子、α-微管蛋白和核输入蛋白等的ε-赖氨酸残基乙酰化侧链的去乙酰化来影响细胞功能, 抑制HDAC活性可以治疗表观遗传异常引起的癌症和其他慢性疾病. 以HDAC抑制剂(HDACi) Chlamydocin为骨架设计合成一类新型抑制剂, 将HDACi的结合区设计为二硫键结构、在环肽中苯丙氨酸的苯环不同位点引入甲基, 合成4种不同序列的环肽类HDACi. 考察HDACi体外抗肿瘤细胞(MCF-7, Hela和7721)活性, 结果表明HDACi对三种肿瘤细胞系均显示良好的生长抑制作用, 细胞形态都发生明显变化, 其中对Hela细胞的毒性最高, IC50达到0.1 μmol/L.

关键词: 组蛋白去乙酰化酶(HDACs), 组蛋白去乙酰化酶抑制剂(HDACi), 环肽, 抗肿瘤细胞活性

Histone deacetylases (HDACs) profoundly affect cellular function by catalyzing removal of acetyl groups from N-acetylated lysine residues of various protein substrates including histones, transcription factors, α-tubulin, and nuclear importers. Inhibition of HDAC activity has emerged as a promising approach for reversing the aberrant epigenetic states associated with cancer and other chronic diseases. To know the structure-activity relationship cyclic peptide HDACi with HDACs, several novel HDACis with similar cyclic tetrapeptide framework as chlamydocin were designed and synthesized. The binding functional group was protected as disulfide. The macrocyclic frameworks were modified by introducing methyl at different sites of benzene ring of phenylalanine. HDACi was tested for cytotoxic activity against three cancer cell lines, including MCF-7, Hela and 7721 cells. All the compounds demonstrated exciting antitumor abilities, and were most active against Hela with IC50 at 0.1 μmol/L. The cellular shapes changed obviously, when the cells treated by HDACi.

Key words: histone deacetylase (HDACs), histone deacetylase inhibitor (HDACi), cyclic peptide, antitumor activity

中图分类号: